EvidenceUpdates: Review: American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone recep Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, September 01, 2010

EvidenceUpdates: Review: American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone recep



CONCLUSION The Update Committee recommends that postmenopausal women with hormone receptor-positive breast cancer consider incorporating AI therapy at some point during adjuvant treatment, either as up-front therapy or as sequential treatment after tamoxifen. The optimal timing and duration of endocrine treatment remain unresolved. The Update Committee supports careful consideration of adverse effect profiles and patient preferences in deciding whether and when to incorporate AI therapy.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.